Stock AnalizOscar Health, Inc. OSCR
Medical Specialities · IPO 2021 · data as of November 13, 2026
Oscar Health, Inc. (OSCR) is a healthcare company listed in the US with a market value of about $9.6B. In the twelve months to September 30, 2026 it had revenue of $17.5B and net income of $855M, a net margin of 4.9%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 13.4, a price to free cash flow of 2.3, 5-year revenue growth of 91% a year, a 5-year average ROIC of -22%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% above the current price.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Checks not passed
- PEG below 1.5
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Interest covered more than 5 times
- Liabilities below 60% of assets
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.5B | $11.7B | $9.2B | $5.9B | $4.0B | $1.8B | $463M | $488M |
| Net income | $855M | -$443M | $25M | -$271M | -$606M | -$573M | -$407M | -$261M |
| Free cash flow | $4.1B | $1.1B | $950M | -$298M | $351M | -$208M | $209M | -$191M |
| EPS (diluted) | $2.32 | $-1.69 | $0.10 | $-1.22 | $-2.85 | $-3.20 | $-14.16 | $-9.06 |
| Net margin | 4.9% | -3.8% | 0.3% | -4.6% | -15.3% | -31.1% | -87.9% | -53.5% |
| ROIC | — | -21.2% | 3.2% | -15.7% | -46.3% | -29.1% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $37.00, 19% above the current price; targets range from $27.00 to $49.00; the consensus rating is “Hold”; expected EPS is $2.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Oscar Health’s P/E ratio?
About 13.4, based on the last twelve months of diluted earnings per share (forward P/E about 13.4).
Is Oscar Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Oscar Health pay a dividend?
Not currently.
Is Oscar Health a good stock to buy?
We do not give buy or sell advice. Oscar Health scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.